EPROBEMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H19ClN2O2
Molecular Weight	282.766
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C(C=C1)C(=O)NCCCN2CCOCC2

InChI

InChIKey=YYFGRAGNYHYWEZ-UHFFFAOYSA-N

InChI=1S/C14H19ClN2O2/c15-13-4-2-12(3-5-13)14(18)16-6-1-7-17-8-10-19-11-9-17/h2-5H,1,6-11H2,(H,16,18)

HIDE SMILES / InChI

Molecular Formula	C14H19ClN2O2
Molecular Weight	282.766
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2054504 | http://www.provizor-online.ru/2013/01/befol_befolum

Eprobemide (brand name Befol/Бефол), a drug used in Russia, is a selective, reversible monoamine oxidase A (MAO) inhibitor, which causes deamination of noradrenaline, serotonin, partially dopamine and β-phenylethylamine, thus increases the content of neurotransmitter monoamines in the central nervous system. Befol does not affect the deaminination of the tyramine and does not cause its accumulation in the body, in contrast to non-selective inhibitors of irreversible action, that is why the drug causes fewer side effects. Befol is used in adults with depression of different nature: endogenous depression in manic-depressive psychosis and various forms of schizophrenia, depression in patients with chronic alcoholism.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Amine oxidase [flavin-containing] A 14 Target ID: P21397 Gene ID: 4128.0 Gene Symbol: MAOA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2054504	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depressive disorder 173 Sources: http://www.provizor-online.ru/2013/01/befol_befolum	Primary		Approved 8429	befol Approved Use Unknown
Manic-depressive disease 9 Sources: http://www.provizor-online.ru/2013/01/befol_befolum	Primary		Approved 8429	befol Approved Use Unknown

PubMed

Title	Date	PubMed
[A comparative study of befol pharmacokinetics in experimental animals and man].	1990 Mar-Apr	2369959
[Mechanism of action of befol on calcium metabolism in cardiomyocytes using the fluorescent probe fura-2].	1996 Mar	8688530
[Effect of befol and sufan on the neurogenic atrial fibrillation].	1998 Apr	9631721
[Anti-arrhythmia activity of befol, sufan, mexidol, and T3-146 in combination with other anti-arrhythmia agents].	1998 May	9644555

Patents

Sample Use Guides

In Vivo Use Guide

Oral or intravenously or intramuscularly. Oral: 2 times a day 30-50 mg (up to 100-150 mg). The daily dose is up to 400 mg. To avoid disturbance of sleep, the second dose should be no later than 18 hours. For prolonged and resistant depressions, treatment begins with intravenous administration of the drug (40-60 drops per minute) or spray (for 1-2 minutes). With intramuscular administration of befol, single doses may be 10-25 mg, daily intake 20-50 mg.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:53:17 GMT 2023` Edited by `admin` on `Sat Dec 16 17:53:17 GMT 2023`
Record UNII	URX5F7RDER
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EPROBEMIDE

Official Name

English

P-CHLORO-N-(3-MORPHOLINOPROPYL)BENZAMIDE

Common Name

English

eprobemide [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C265